213 related articles for article (PubMed ID: 28795418)
41.
Krencz I; Sztankovics D; Sebestyén A; Pápay J; Dankó T; Moldvai D; Lutz E; Khoor A
Pathol Oncol Res; 2024; 30():1611593. PubMed ID: 38706776
[No Abstract] [Full Text] [Related]
42. Pan-cancer analysis of
Huang RSP; Decker B; Murugesan K; Hiemenz M; Mata DA; Li G; Creeden J; Ramkissoon SH; Ross JS
J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34130989
[TBL] [Abstract][Full Text] [Related]
43. Immune checkpoint blockade as a potential therapeutic strategy for undifferentiated malignancies.
Devereaux KA; Charu V; Zhao S; Charville GW; Bangs CD; van de Rijn M; Cherry AM; Natkunam Y
Hum Pathol; 2018 Dec; 82():39-45. PubMed ID: 30539796
[TBL] [Abstract][Full Text] [Related]
44. Pan-cancer landscape of
Huang RSP; Murugesan K; Montesion M; Pavlick DC; Mata DA; Hiemenz MC; Decker B; Frampton G; Albacker LA; Ross JS
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33972391
[TBL] [Abstract][Full Text] [Related]
45. Comparison of 22C3 PD-L1 Expression between Surgically Resected Specimens and Paired Tissue Microarrays in Non-Small Cell Lung Cancer.
Li C; Huang C; Mok TS; Zhuang W; Xu H; Miao Q; Fan X; Zhu W; Huang Y; Lin X; Jiang K; Hu D; Chen X; Huang P; Lin G
J Thorac Oncol; 2017 Oct; 12(10):1536-1543. PubMed ID: 28751245
[TBL] [Abstract][Full Text] [Related]
46. Association Between Formalin Fixation Time and Programmed Cell Death Ligand 1 Expression in Patients With Non-Small Cell Lung Cancer.
Kawachi H; Fujimoto D; Yamashita D; Fukuoka J; Kitamura Y; Hosoya K; Sato Y; Nagata K; Nakagawa A; Tachikawa R; Date N; Sakanoue I; Hamakawa H; Takahashi Y; Tomii K
Anticancer Res; 2019 May; 39(5):2561-2567. PubMed ID: 31092453
[TBL] [Abstract][Full Text] [Related]
47. Inter-relationship between PD-L1 expression and clinic-pathological features and driver gene mutations in pulmonary sarcomatoid carcinomas.
Lococo F; Torricelli F; Rossi G; Alifano M; Damotte D; Rapicetta C; Tamagnini I; Cavazza A; Piana S; Galeone C; Paci M; Ciarrocchi A
Lung Cancer; 2017 Nov; 113():93-101. PubMed ID: 29110857
[TBL] [Abstract][Full Text] [Related]
48. Programmed cell death-ligand 1 expression in surgically resected stage I pulmonary adenocarcinoma and its correlation with driver mutations and clinical outcomes.
Yang CY; Lin MW; Chang YL; Wu CT; Yang PC
Eur J Cancer; 2014 May; 50(7):1361-9. PubMed ID: 24548766
[TBL] [Abstract][Full Text] [Related]
49. PD-L1 copy number gain in nonsmall-cell lung cancer defines a new subset of patients for anti PD-L1 therapy.
Goldmann T; Kugler C; Reinmuth N; Vollmer E; Reck M
Ann Oncol; 2016 Jan; 27(1):206-7. PubMed ID: 26487587
[No Abstract] [Full Text] [Related]
50. Chemotherapy enhances programmed cell death 1/ligand 1 expression via TGF-β induced epithelial mesenchymal transition in non-small cell lung cancer.
Funaki S; Shintani Y; Kawamura T; Kanzaki R; Minami M; Okumura M
Oncol Rep; 2017 Oct; 38(4):2277-2284. PubMed ID: 28849209
[TBL] [Abstract][Full Text] [Related]
51. Agreement between Programmed Cell Death Ligand-1 Diagnostic Assays across Multiple Protein Expression Cutoffs in Non-Small Cell Lung Cancer.
Ratcliffe MJ; Sharpe A; Midha A; Barker C; Scott M; Scorer P; Al-Masri H; Rebelatto MC; Walker J
Clin Cancer Res; 2017 Jul; 23(14):3585-3591. PubMed ID: 28073845
[No Abstract] [Full Text] [Related]
52. PD-L1 gene copy number and promoter polymorphisms regulate PD-L1 expression in tumor cells of non-small cell lung cancer patients.
Krawczyk P; Grenda A; Wojas-Krawczyk K; Nicoś M; Kucharczyk T; Jarosz B; Reszka K; Pankowski J; Krukowska K; Bożyk A; Szumiło J; Sawicki M; Trojanowski T; Milanowski J
Cancer Genet; 2019 Sep; 237():10-18. PubMed ID: 31447062
[TBL] [Abstract][Full Text] [Related]
53. Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma.
Green MR; Monti S; Rodig SJ; Juszczynski P; Currie T; O'Donnell E; Chapuy B; Takeyama K; Neuberg D; Golub TR; Kutok JL; Shipp MA
Blood; 2010 Oct; 116(17):3268-77. PubMed ID: 20628145
[TBL] [Abstract][Full Text] [Related]
54. PD-L1 gene polymorphism and high level of plasma soluble PD-L1 protein may be associated with non-small cell lung cancer.
Cheng S; Zheng J; Zhu J; Xie C; Zhang X; Han X; Song B; Ma Y; Liu J
Int J Biol Markers; 2015 Nov; 30(4):e364-8. PubMed ID: 26349666
[TBL] [Abstract][Full Text] [Related]
55. Prognostic Value of Programmed Death Ligand 1 and Programmed Death 1 Expression in Thymic Carcinoma.
Yokoyama S; Miyoshi H; Nakashima K; Shimono J; Hashiguchi T; Mitsuoka M; Takamori S; Akagi Y; Ohshima K
Clin Cancer Res; 2016 Sep; 22(18):4727-34. PubMed ID: 27166394
[TBL] [Abstract][Full Text] [Related]
56. MUC1-C integrates PD-L1 induction with repression of immune effectors in non-small-cell lung cancer.
Bouillez A; Rajabi H; Jin C; Samur M; Tagde A; Alam M; Hiraki M; Maeda T; Hu X; Adeegbe D; Kharbanda S; Wong KK; Kufe D
Oncogene; 2017 Jul; 36(28):4037-4046. PubMed ID: 28288138
[TBL] [Abstract][Full Text] [Related]
57. Aligning digital CD8
Conde E; Caminoa A; Dominguez C; Calles A; Walter S; Angulo B; Sánchez E; Alonso M; Jimenez L; Madrigal L; Hernando F; Sanz-Ortega J; Jimenez B; Garrido P; Paz-Ares L; de Castro J; Hernandez S; Lopez-Rios F
Histopathology; 2018 Jan; 72(2):270-284. PubMed ID: 28815764
[TBL] [Abstract][Full Text] [Related]
58. IFN-gamma-induced PD-L1 expression in melanoma depends on p53 expression.
Thiem A; Hesbacher S; Kneitz H; di Primio T; Heppt MV; Hermanns HM; Goebeler M; Meierjohann S; Houben R; Schrama D
J Exp Clin Cancer Res; 2019 Sep; 38(1):397. PubMed ID: 31506076
[TBL] [Abstract][Full Text] [Related]
59. 9p24.1 alterations and programmed cell death 1 ligand 1 expression in early stage unfavourable classical Hodgkin lymphoma: an analysis from the German Hodgkin Study Group NIVAHL trial.
Gerhard-Hartmann E; Goergen H; Bröckelmann PJ; Mottok A; Steinmüller T; Grund J; Zamò A; Ben-Neriah S; Sasse S; Borchmann S; Fuchs M; Borchmann P; Reinke S; Engert A; Veldman J; Diepstra A; Klapper W; Rosenwald A
Br J Haematol; 2022 Jan; 196(1):116-126. PubMed ID: 34520052
[TBL] [Abstract][Full Text] [Related]
60. The expression of PD-L1 protein as a prognostic factor in lung squamous cell carcinoma.
Takada K; Okamoto T; Toyokawa G; Kozuma Y; Matsubara T; Haratake N; Akamine T; Takamori S; Katsura M; Shoji F; Oda Y; Maehara Y
Lung Cancer; 2017 Feb; 104():7-15. PubMed ID: 28213003
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
